Latest News

Fibronostics is proud to partner with the American Liver Foundation to bring you an easy screening tool for fatty liver disease.

Fibronostics have partnered with the American Liver Foundation to bring you an easy screening tool for fatty liver disease. You can take ALF’s new #ThinkLiverThinkLife
Read more

Latest News

Fibronostics is proud to partner with the American Liver Foundation to bring you an easy screening tool for fatty liver disease.

Fibronostics have partnered with the American Liver Foundation to bring you an easy screening tool for fatty liver disease. You can take ALF’s new #ThinkLiverThinkLife
Read more

Latest News

Fibronostics Secures Financing, Announces New CEO

Fibronostics, a global leader in non-invasive, AI-driven diagnostics for NASH patients, announced today it has secured $6.5 million in funding. In addition to the financing, Sven
Read more
Latest News

Fibronostics is proud to partner with the American Liver Foundation to bring you an easy screening tool for fatty liver disease.

Fibronostics have partnered with the American Liver Foundation to bring you an easy screening tool for fatty liver disease. You can take ALF’s new #ThinkLiverThinkLife quiz to see whether you or a loved one could be at risk for fatty liver disease, which usually has no symptoms unless or until
Read more

Fibronostics is proud to partner with the American Liver Foundation to bring you an easy screening tool for fatty liver disease.

Fibronostics is proud to announce today that it has secured $6.5 million in funding. In addition – Sven Henrichwark, PhD, has been named the company’s new CEO.

Fibronostics will be presenting 2 of our clinical studies at the International Liver Congress™ 2022 of the European Association for the Study of the Liver (EASL).

AASLD Poster: Comparing Non-Invasive Tools – LIVERFASt™, FIB-4 and Transient Elastography in Sequential and Combinatory Pathways for NAFLD.

AASLD Poster: Long-term prognosis of patients with metabolic dysfunction – associated fatty liver disease by non-invasive methods.

ADA 2021: LIVERFAStTM Has Similar Performance to Liver Biopsy for the Screening of NASH Fibrosis in Type 2 Diabetes Mellitus (T2D).

Fibronostics is proud to partner with the American Liver Foundation to bring you an easy screening tool for fatty liver disease.

Fibronostics is proud to announce today that it has secured $6.5 million in funding. In addition – Sven Henrichwark, PhD, has been named the company’s new CEO.